Pfizer's backer Sir Richard Sykes has been wrong before on drugs firm deals

Outlook As any salesman will tell you, there's nothing like a testimonial to convince a potential buyer. Which is why the highly paid executives Pfizer has hired to flog its takeover of AstraZeneca have found two cheerleaders (only two, mind) to recommend their offer. Both are quoted at length on Pfizer's page-long sales pitch posted on its website.

One is Ian Read. He says the merger would see the two companies' operations in Oxford, Cambridge and London retain their "Golden Triangle" status and be a key part of the combined global business. But Mr Read is the chief executive of Pfizer, so his views are perhaps biased.

The other is Sir Richard Sykes, the former chairman and chief executive of GlaxoSmithKline. Sir Richard describes the merger as a "fantastic opportunity to work in a country with a scientific background". At least, the presentation makes it look like that's what he said. In fact, reading the small print, he seems to have been talking in more general terms about the UK. But hey, that's advertising.

The copywriter's sleight of hand aside, Sir Richard has been one of the few big guns in industry to commend the takeover. Other dignitaries, from Sir Michael Heseltine to Lord Sainsbury, have been vehemently opposed. So Sir Richard is to be applauded for having the guts not to go with the flow. For standing up against the noisy consensus.

It wasn't so, though, when he was chief executive of Glaxo Wellcome and brought his company into the arms of SmithKline Beecham in 2000. That deal, which also created the world's biggest drugs company, ended up being one of the most value destructive, not to mention job destructive. But at the time, Sir Richard trumpeted its "unbelievable financial power" and "vision".

A few years later, when the deal was looking like a flop, Sir Richard admitted he was railroaded by the clamour of investment bankers and fund managers demanding it. Actually, he disclosed, he never really wanted a merger at all. He even penned a report concluding "growth for growth's sake via takeovers has been a prime cause of shareholder value destruction".

Pfizer argues, of course, that this is not just a deal about "growth for growth's sake". It's about avoiding US taxes too.

But let's put that multi-billion dollar tax bonus to one side. Pfizer highlights other selling points: the deal will, it says, "speed development of treatments". Unlikely: scientists fear the merger will disrupt funding of potentially successful projects and disband close-knit research teams.

It talks of how the deal will "deepen research efforts". AstraZeneca employees read that as "merge R&D teams". No thanks.

It says it will strengthen areas like oncology. Translation: "give Pfizer shareholders a chunk of the benefits of AstraZeneca's cancer breakthroughs."

Note to the Coalition leaders: it wasn't just Sir Richard who called the Glaxo deal wrong in 2000. MPs on the Science Select Committee gave it a ringing endorsement, too. Many scientists didn't. They said from the start that merging Glaxo and SmithKline was a pointlessly risky exercise.

Now, they seem to think this deal is crazy too. Perhaps we should take notice.

Start your day with The Independent, sign up for daily news emails
PROMOTED VIDEO
ebooks
ebooksA special investigation by Andy McSmith
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Software Development Manager

£40000 - £50000 per annum: Recruitment Genius: This is an exciting opportunity...

Ashdown Group: Product Manager - (Product Marketing, Financial Services)

£30000 - £35000 per annum + Benefits: Ashdown Group: Marketing Manager - Marke...

Recruitment Genius: Compliance Assistant

£13000 per annum: Recruitment Genius: This Pension Specialist was established ...

Ashdown Group: Market Research Executive

£23000 - £26000 per annum + Benefits: Ashdown Group: Market Research Executive...

Day In a Page

Isis hostage crisis: The prisoner swap has only one purpose for the militants - recognition its Islamic State exists and that foreign nations acknowledge its power

Isis hostage crisis

The prisoner swap has only one purpose for the militants - recognition its Islamic State exists and that foreign nations acknowledge its power, says Robert Fisk
Missing salvage expert who found $50m of sunken treasure before disappearing, tracked down at last

The runaway buccaneers and the ship full of gold

Salvage expert Tommy Thompson found sunken treasure worth millions. Then he vanished... until now
Homeless Veterans appeal: ‘If you’re hard on the world you are hard on yourself’

Homeless Veterans appeal: ‘If you’re hard on the world you are hard on yourself’

Maverick artist Grayson Perry backs our campaign
Assisted Dying Bill: I want to be able to decide about my own death - I want to have control of my life

Assisted Dying Bill: 'I want control of my life'

This week the Assisted Dying Bill is debated in the Lords. Virginia Ironside, who has already made plans for her own self-deliverance, argues that it's time we allowed people a humane, compassionate death
Move over, kale - cabbage is the new rising star

Cabbage is king again

Sophie Morris banishes thoughts of soggy school dinners and turns over a new leaf
11 best winter skin treats

Give your moisturiser a helping hand: 11 best winter skin treats

Get an extra boost of nourishment from one of these hard-working products
Paul Scholes column: The more Jose Mourinho attempts to influence match officials, the more they are likely to ignore him

Paul Scholes column

The more Jose Mourinho attempts to influence match officials, the more they are likely to ignore him
Frank Warren column: No cigar, but pots of money: here come the Cubans

Frank Warren's Ringside

No cigar, but pots of money: here come the Cubans
Isis hostage crisis: Militant group stands strong as its numerous enemies fail to find a common plan to defeat it

Isis stands strong as its numerous enemies fail to find a common plan to defeat it

The jihadis are being squeezed militarily and economically, but there is no sign of an implosion, says Patrick Cockburn
Virtual reality thrusts viewers into the frontline of global events - and puts film-goers at the heart of the action

Virtual reality: Seeing is believing

Virtual reality thrusts viewers into the frontline of global events - and puts film-goers at the heart of the action
Homeless Veterans appeal: MP says Coalition ‘not doing enough’

Homeless Veterans appeal

MP says Coalition ‘not doing enough’ to help
Larry David, Steve Coogan and other comedians share stories of depression in new documentary

Comedians share stories of depression

The director of the new documentary, Kevin Pollak, tells Jessica Barrett how he got them to talk
Has The Archers lost the plot with it's spicy storylines?

Has The Archers lost the plot?

A growing number of listeners are voicing their discontent over the rural soap's spicy storylines; so loudly that even the BBC's director-general seems worried, says Simon Kelner
English Heritage adds 14 post-war office buildings to its protected lists

14 office buildings added to protected lists

Christopher Beanland explores the underrated appeal of these palaces of pen-pushing
Human skull discovery in Israel proves humans lived side-by-side with Neanderthals

Human skull discovery in Israel proves humans lived side-by-side with Neanderthals

Scientists unearthed the cranial fragments from Manot Cave in West Galilee